Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients
Retrieved on:
Wednesday, June 23, 2021
Medical devices, Surgery, Hospitals, FDA, Public relations, Investor relations, Communications, Cardiology, Radiology, General Health, Health, Medicine, Cardiovascular system, Clinical medicine, Thrombectomy, Penumbra, Ischemia, Stroke, Thrombus, Aspiration, the Penumbra System, Penumbra, THE PENUMBRA SYSTEM, PENUMBRA
RED 62 is designed to navigate complex distal vessel anatomy and deliver powerful aspiration, together with Penumbra ENGINE, for the removal of blood clots in acute ischemic stroke patients with large vessel occlusions.
Key Points:
- RED 62 is designed to navigate complex distal vessel anatomy and deliver powerful aspiration, together with Penumbra ENGINE, for the removal of blood clots in acute ischemic stroke patients with large vessel occlusions.
- The performance and length of RED 62 enable me to address a broader group of patients using aspiration thrombectomy to remove blood clots and improve my patients health outcomes.
- With the continued success of aspiration thrombectomy, physicians asked us to address navigation in more challenging distal vessels.
- Penumbra, the Penumbra P logo, Penumbra ENGINE, RED, and 3D Revascularization Device are trademarks of Penumbra, Inc. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn .